2023 Molecular Imaging Preview

Road to RSNA 2023: Molecular Imaging
By Will Morton
This is just the third year that RSNA has offered a dedicated track on nuclear medicine and molecular imaging, with eight scientific sessions covering research in prostate cancer imaging, breast cancer, cardiovascular and pulmonary imaging, and more.
November 16, 2023
Road To Rsna
Can AI predict treatment response in patients with prostate cancer?
By Will Morton
An AI model based on F-18 DCFPyL PSMA-PET/CT images will be presented here that shows promise for predicting treatment response in patients with metastatic castration-resistant prostate cancer.
November 15, 2023
Does contrast media used with PET/MRI make a difference?
By Will Morton
Findings presented during this session suggest that the use of MRI contrast agents during PET/MRI exams has no additional positive benefit for primary and follow-up staging of pediatric lymphoma patients.
November 15, 2023
Can FDG-PET/MRI radiomics help diagnose rhabdomyosarcoma in children?
By Will Morton
In this session on pediatrics and general oncology, a study will be presented that explored the value of F-18 FDG-PET/MRI radiomics features in predicting rhabdomyosarcoma in children.
November 15, 2023
FDG-PET reveals patterns in newly recognized fused in sarcoma proteinopathy
By Will Morton
FDG-PET may help differentiate patients with fused in sarcoma, a newly recognized proteinopathy causing progressive dementia, from those with Alzheimer’s disease and frontotemporal dementia, according to this presentation.
November 15, 2023
PET/CT shows value in patients after thoracic vascular graft surgery
By Will Morton
PET/CT imaging in patients after thoracic aortic graft surgery reveals F-18 FDG radiotracer uptake patterns that can indicate infections, according to a presentation in this session.
November 15, 2023
Ultra-early phase scintigraphy detects ATTR cardiac amyloidosis
By Will Morton
Bone scintigraphy can detect transthyretin protein accumulation associated with cardiac amyloidosis just five minutes after patients are injected with technetium-99m pyrophosphate radiotracer, according to research to be presented in this session.
November 15, 2023
F-18 fluciclovine vs. Ga-68 PSMA: Which tracer is superior in metastatic breast cancer?
By Will Morton
F-18 fluciclovine PET/CT imaging results in greater metastases detection in women with invasive lobular carcinoma of the breast than Ga-68 PSMA-PET/CT, while both are superior to conventional imaging, according to this presentation.
November 15, 2023
Which approach is best in newly diagnosed breast cancer?
By Will Morton
A study will be presented in this session that compared whole-body MRI, whole-body F-18 FDG-PET/MRI, and conventional imaging for staging women with newly diagnosed breast cancer.
November 15, 2023
Ga-68 RM2-PET effective in prostate cancer relapse cases
By Will Morton
Gallium-68 (Ga-68) RM2-PET imaging should be considered in patients with biochemical recurrent prostate cancer to aid in disease detection and management decisions, according to a study to be presented in this session.
November 15, 2023
Page 1 of 1